Clearside Biomedical has reported positive topline results from the TYBEE trial, a Phase ll clinical study designed to analyse suprachoroidal CLS-TA with intravitreally administered Eylea (aflibercept) in patients with diabetic macular edema (DME).

The multicentre, randomised, masked, controlled trial had a six-month-long evaluation period and enrolled 71 treatment-naïve patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As part of the trial, patients were randomised at 1:1 ratio to receive either quarterly treatments of suprachoroidal CLS-TA together with intravitreal Eylea (the combination arm) or four monthly treatments of intravitreal Eylea plus a sham suprachoroidal procedure (the control arm).

Patients in either arm received intravitreal Eylea treatment at months four and five as needed.

The TYBEE trial met its primary objective of mean improvement in best corrected visual acuity (BCVA) from baseline over six months as measured using the Early Treatment of Diabetic Retinopathy Trial (ETDRS) scale.

“The multicentre, randomised, masked, controlled trial had a six-month long evaluation period and enrolled 71 treatment naïve patients.”

Patients in the combination arm have also gained an average of 12.3 ETDRS letters compared to 13.5 ETDRS letters in the Elyea alone control arm.

Furthermore, the administration of suprachoroidal CLS-TA along with intravitreal Eylea met a key secondary objective of the trial with a mean reduction from baseline of 208 microns in central subfield thickness (CST) of the retina at six months, compared to a 177 micron mean reduction in the control arm.

A total of 93% of patients in the combination arm also experienced more than 50% reduction in excess CST at six months, compared to 73% of patients in the control arm.

The trial also found that suprachoroidal CLS-TA used together with intravitreal Eylea was generally well tolerated, with no treatment-related serious adverse events reported through the trial’s 24-week evaluation period.

It reported elevated intraocular pressure adverse events for 8.3% of patients in the combination arm, compared to 2.9% of patients in the control arm.

Both arms of the trial reported cataract adverse events, with about 5.6% of patients in the combination arm and 2.9% of patients in the control arm developing cataracts.